Alnylam

@Alnylam

Alnylam is the world’s leading RNAi therapeutics company. We believe that patients living with life-threatening diseases deserve innovative new treatments.

Cambridge, MA
Vrijeme pridruživanja: kolovoz 2009.

Tweetovi

Blokirali ste korisnika/cu @Alnylam

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @Alnylam

  1. 31. sij

    We’re pleased to announce that we’ve received a positive opinion from the EMA () Committee for Medicinal Products for Human Use () for our investigational therapeutic for the treatment of the acute hepatic .

    Poništi
  2. 30. sij

    Acute hepatic (AHP) refers to a family of rare, often misdiagnosed genetic diseases characterized by potentially life-threatening attacks and, for some patients, chronic debilitating symptoms that negatively impact daily functioning and quality of life.

    Poništi
  3. proslijedio/la je Tweet
    29. sij

    Thanks and for highlighting the story as one of the successes in the Boston/Cambridge ecosystem! There is no better place in the world to make a medicine than right here!

    Poništi
  4. 22. sij

    Symptoms of acute hepatic (AHP) can often lead to misdiagnoses of more common conditions such as IBS, fibromyalgia, appendicitis & endometriosis. As a result, patients often remain w/o a proper diagnosis for up to 15 yrs.

    Poništi
  5. proslijedio/la je Tweet
    16. sij
    Poništi
  6. 15. sij

    We're to welcome our first Co-op class of the new decade! This outstanding group of 33 co-ops and legal externs represents , and . Learn more about career development at Alnylam here:

    Poništi
  7. 13. sij

    PH1 of a Kind is a 4-part video series for kids, about kids from around the world who have been diagnosed with primary hyperoxaluria type 1 (PH1). The videos star Isabelle, Luuk, Asha and Will and each tackles a different challenge they face living with this .

    Poništi
  8. 12. sij

    This afternoon, we announced preliminary Q4 and full year 2019 global net product revenues and additional updates. Tune in to our live webcast tomorrow at 1:30 PM ET/10:30 AM PT to learn more. Access the webcast here:

    Poništi
  9. 10. sij

    We're pleased to announce today that we've initiated a rolling submission of a New Drug Application (NDA) to the for lumasiran, an investigational therapeutic for the treatment of primary type 1 (PH1).

    Poništi
  10. 10. sij

    Peggy’s life partner Dan, who is living with , inspired her to convey the puzzling challenges of the disease through an original artwork as part of the “The Art of Living with hATTR Amyloidosis” project. They discuss their story in a new Q&A.

    Poništi
  11. 9. sij

    We're headed to San Francisco for where we'll present (and webcast) a company overview and share an update on unaudited 4th quarter and full year 2019 global net product revenues. A Q&A breakout session will follow immediately.

    Poništi
  12. 8. sij

    People who may have the primary type 1 can talk to their doctor about Alnylam Act’s no-cost, 3rd-party genetic testing & counseling. Alnylam Act may help accelerate or confirm a PH1 diagnosis so families can make informed decisions about their health.

    Poništi
  13. 8. sij

    New year! New role? We've got >150 open roles in the US, Europe and Asia including many in research, clinical development, clinical operations, quality, medical affairs and manufacturing. Perhaps this is YOUR moment to join a leader that is also a recognized top employer.

    Poništi
  14. proslijedio/la je Tweet
    31. pro 2019.

    Thrilled to see the arrival of gene silencing medicines (our therapeutics) included in this great recap of important breakthroughs in medical science in 2019 by !

    Poništi
  15. 2. sij

    “Living a Rare Life” is the story of one family’s journey to unlock the mysteries of a life-threatening genetic called and how examining their health history across generations proved to be critical.

    Poništi
  16. 2. sij

    As we enter the new decade, we look forward to seeing the incredible biomedical breakthroughs from our industry to come and look back with pride on our contribution to the innovations of the past decade. And is just getting started!

    Poništi
  17. 26. pro 2019.

    Supporting patient access to innovative treatments is at the core of our Patient Access Philosophy and our head of Patient Services discusses how her team works with patients in many ways to help them navigate the evolving complexities of today’s healthcare system in a new Q&A.

    Poništi
  18. 21. pro 2019.

    For many people, like CeCe, it can take years to be accurately diagnosed with amyloidosis. Click the link below to learn more about CeCe’s story, the signs and symptoms of this and the importance of having meaningful conversations with your doctor.

    Poništi
  19. 21. pro 2019.

    Congrats to our CEO on being voted the 2019 best CEO. His passion for our science and unwavering commitment to helping people living with disease motivates and inspires us every day...and has since 2002!

    Poništi
  20. proslijedio/la je Tweet
    20. pro 2019.
    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·